Literature DB >> 31366437

In Reply.

Jan Beyer-Westendorf.   

Abstract

Year:  2019        PMID： 31366437      PMCID： PMC6683441          DOI： 10.3238/arztebl.2019.0420b

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

Review 1.  External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?

Authors:  J Beyer-Westendorf; H Büller
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

2.  Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.

Authors:  T van der Hulle; P L den Exter; B Planquette; G Meyer; S Soler; M Monreal; D Jiménez; A K Portillo; C O'Connell; H A Liebman; M Shteinberg; Y Adir; M Tiseo; M Bersanelli; H N Abdel-Razeq; A H Mansour; O G Donnelly; G Radhakrishna; S Ramasamy; G Bozas; A Maraveyas; A B Shinagare; H Hatabu; M Nishino; M V Huisman; F A Klok
Journal:  J Thromb Haemost       Date:  2016-01-11       Impact factor: 5.824

Review 3.  Incidental venous thromboembolism: is anticoagulation indicated?

Authors:  Marcello Di Nisio; Marc Carrier
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism.

Authors:  Jan Beyer-Westendorf; Robert Klamroth; Stephan Kreher; Florian Langer; Axel Matzdorff; Hanno Riess
Journal:  Dtsch Arztebl Int       Date:  2019-01-18       Impact factor: 5.594
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.